+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ficerafusp alfa combined with pembrolizumab compared to placebo with pembrolizumab in adults with first-line PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma HNSCC. This study targets two cancer drivers, EGFR and TGF-beta, to address tumor growth and spread. It includes phase 2 to find the best dose and phase 3 to compare treatment outcomes. In phase 2, participants are randomly assigned to one of three groups ficerafusp alfa 1500 mg weekly plus pembrolizumab every three weeks, ficerafusp alfa 750 mg weekly plus pembrolizumab every three weeks, or placebo weekly plus pembrolizumab every three weeks. Phase 3 uses the optimal dose of ficerafusp alfa with pembrolizumab versus placebo with pembrolizumab in a 21 ratio. Treatments continue with scheduled dosing during each phase. Participants undergo regular assessments including scans to measure tumor response by RECIST 1.1 criteria, safety monitoring for side effects, and quality of life questionnaires. The study tracks objective response rate, overall survival, progression-free survival, and other measures over up to three years. Safety is closely monitored for treatment-related adverse events during and after therapy. Total participation may last several years depending on treatment and follow-up.

Age: 18Years +All GendersPhase 2Phase 3
231 locations